Immunotherapy utilizing CAMPATH-1H for patients with chemotherapy-refractory chronic lymphocytic leukemia has yielded encouraging results with many reports of complete remission. Here we report the outcome of two patients with CD4-positive T cell prolymphocytic leukemia treated with CAM-PATH-1H. Both patients responded rapidly to treatment and subsequently developed CD4 lymphopenia. One patient remained in complete remission after 14 weeks of treatment. Serial peripheral blood flow cytometry revealed that the CD52 antigen was present throughout treatment. The other patient who was initially CD52-positive, became CD52-negative after 6 weeks of treatment, and developed progressive symptoms of T cell prolymphocytic leukemia. Immunotherapy was stopped, chemotherapy proved futile, and the patient died. This change in phenotype from CD52-positive to -negative during CAM-PATH-1H therapy points out a need to develop strategies for maintaining antigenic expression during monoclonal antibody therapy. Leukemia (2002) 16, 861-864.
Introduction
CD52 antigen is a glycosylated, phosphatidylinositolglycan (PIG)-anchored glycoprotein (PIG-AP) with a protein sequence of 12 amino acids. 1 In humans, it is expressed on normal and neoplastic lymphocytes, monocytes and macrophages, but not erythrocytes and hematopoetic stem cells. 2, 3 It is present in a majority of B cell malignancies, most cases of T cell and B cell prolymphocytic leukemia (PLL) and some cases of acute myelogenous and lymphocytic leukemias. 4, 5 Immunotherapy with monoclonal antibodies (MoAbs) targeted at CD52 can be clinically useful. 4, 6, 7 CD52 is an excellent therapeutic target because of its abundant expression (approximately 4.5 × 10 6 molecules per lymphocyte), its close apposition to the cell membrane, and its apparent lack of modulation. 1, 8 CAMPATH-1H is a humanized monoclonal immunoglobulin (Ig) G1 MoAb directed against CD52. 2, 4, 8, 9 In vitro, CAM-PATH-1H causes cell lysis using host effector mechanisms. 2, 4, 10 Therapeutic activity has been shown in autoimmune disorders, 7 refractory inflammatory disease, 11 allograft T cell depletion in bone marrow transplantation, 12 and hematolymphoid malignancies. 13 Studies are ongoing with CAMPATH-1H therapy for patients with chemotherapy refractory chronic lymphocytic leukemia (CLL), with reports of complete remissions (CRs). 5, 14 T-PLL is a malignancy of T cells with distinctive clinical, cytologic and cytogenic features. 15 It is aggressive and refrac- tory to conventional cytotoxic chemotherapy. Median survival is 7.5 months. 16 Nondurable responses to the purine analogues, particularly deoxycoformycin (DCF), have been reported. 15, 17 CAMPATH-1H therapy can result in a superior response rate compared with DCF in patients with refractory T-PLL. 16 A durable CR rate of 60% was reported. In three relapsed patients retreatment resulted in second CRs, two of whom were successfully autografted with hematopoetic stem cells collected during the first CR. Patients who failed treatment with CAMPATH-1H exhibited severe bone marrow aplasia and pancytopenia of unknown cause.
We report the use of CAMPATH-1H as initial therapy in two patients with T-PLL. One of these patients demonstrated the emergence of a CD52-negative clone resistant and, as a consequence, was refractory to CAMPATH-1H therapy. Use of CAMPATH-1H has resulted in CD52-negative populations emerging in rheumatoid arthritis and non-Hodgkin's lymphoma patients. 18, 19 This is the first reported case of phenotypic conversion of leukemic cells from CD52-positive to CD52-negative during CAMPATH-1H therapy in T-PLL. Aspects of this case provide insight into mechanisms of treatment failure.
Study design
Peripheral blood was drawn from two patients with T-PLL and shipped as EDTA whole blood to Cytometry Associates (Brentwood, TN, USA) for lymphoma/leukemia phenotyping. Tests were performed in accordance with the recommendations of the US-Canadian Consensus Conference on the Immunophenotypic Analysis of Hematologic Neoplasia by Flow Cytometry. 20, 21 Anti-CD52 MoAb was obtained from Serotec (Raleigh, NC, USA).
Both patients were enrolled in institutional review board (IRB)-approved clinical studies at the Marshfield Clinic Oncology Center. CAMPATH-1H was obtained from Millennium and ILEX Partners, Cambridge, MA, USA.
Results and discussion
A 62-year-old white female presented in January 2000 with fatigue, anemia and a white blood count of 249 000. Peripheral blood flow cytometry on 21 January 2000 demonstrated mature (post-thymic) T cell malignancy positive for CD52, CD2, CD3, CD7, CD4 and HLA-DR, and negative for CD5, CD8, TdT and B cell markers consistent with T-PLL (Table  1) . 15, 21 The demonstration of CD52 expression was strong with 100% of the cells positive and staining with bright intensity. Cytogenetics showed 11 of 21 cells with large pericentric inversion of chromosome 6, and a subclone of seven cells also having an inverted 1p duplication. 
Therapy was initiated with leukopheresis followed by CAM-PATH-1H from 11 February 2000 to 19 April 2000, with an initial test dose of 3 mg, followed by 10 mg 2 days later, and beginning on day 5, 30 mg three times a week for 9 weeks.
She responded briskly, becoming neutropenic after 1 week. However, 7 weeks into therapy she developed fevers and a new pre-auricular adenopathy. Over the next 2 weeks she developed progressive fevers, night sweats and liver function test abnormalities. Liver biopsy showed extensive portal and sinusoidal involvement by T-PLL. Lymph node biopsy and repeat peripheral blood flow cytometry on 17 April 2000 revealed recurrent disease with loss of CD52-positivity (Table 1, Figure 1) . B lymphoid cells were virtually absent (0.1% of all cells in the specimen). Only 4% of mature T cells displayed an antigenic profile similar to that on 21 January 2000. The remainder were CD52 negative.
CAMPATH-1H was discontinued and chemotherapy was initiated with 2-CDA without response. On 3 May 2000, 2 weeks after termination of CAMPATH-1H treatment, two populations of CD52-negative CD3 cells had emerged (Table 1, Figure 1 ). At this point 92% of the population of T cells were CD52-negative. The DNA content analysis of all cells showed an aneuploid pattern (14% of all cells). There was a predominant population of T cells present displaying the aberrant antigenic profile. There was a subpopulation with increased cell size and aneuploidy, suggesting an evolving secondary clone. These cells were also negative for expression of CD52.
Serial testing for CD52 status remained negative 7 weeks (ie on 8 June 2000) after the discontinuation of CAMPATH-1H (Table 1, Figure 1 ). More than 98% of the cells in the specimen were tumor cells. The composite phenotype of the tumor cells had been established to be CD2
Because the specimen from 3 May 2000 had demonstrated a bimodal expression of CD3, it was felt that CD52 should be looked at in the context of the other pan-T cell marker expressed by the tumor (ie CD2). In this way, an evaluation of CD52 expression on a positively identified tumor cell would be ensured. CD3 was assessed on this specimen as well, and it was uniformly brightly positive on all tumor cells with no evidence of the bimodal distribution seen in the previous specimen.
Repeat cytogenetics showed evidence of clonal progression with a subclone having 78 to 82 chromosomes. The DNA In September 1998, a second patient, an 83-year-old white male presented with a white blood count of 42 000, a platelet count of 161, and a hemoglobin of 15.2. His medical history included resected melanoma, metastatic prostate carcinoma, resected thyroid carcinoma and hemangiopericytoma. Peripheral blood flow cytometry showed expression of CD2, CD4, CD5 and CD7 with aberrant loss of CD3. CD8, TdT and B cell markers were negative. On the basis of this aberrant phenotype, a diagnosis of T-PLL was made.
Therapy with CAMPATH-1H antibody was initiated in October 1998 and continued for 12 weeks in conjunction with combined androgen blockade. He responded briskly to therapy with the development of CD4 lymphopenia for which he received antibiotic and anti-viral prophylaxis until January 2000.
Repeat peripheral blood flow cytometry in January 1999
showed a CR. However, in January 2000, early recurrence became apparent, but clinically the patient has remained stable. His complete blood count in June 2000 showed a white blood count of 13.9, hemoglobin of 13.9, and a platelet count of 245 000 with a normal differential. CD52 antigen testing has remained positive.
Little is known about antigenic changes in relapsed postthymic leukemias or lymphomas. This is the first reported instance of true phenotypic transformation from positive to negative CD52 antigenicity in human leukemic T cells associated with CAMPATH-1H therapy. The consequences were critical.
CAMPATH-1H attaches to CD52-positive B and T cells resulting in their rapid clearance. After the CD52-positive cells are cleared, a population of persistent CD52-negative B and T cells sometimes emerges. 18, 19, 22 Emergent cells exhibit a severe defect in the synthesis of a glycosylphosphatidylinositol (GPI) precursor resulting in defective surface expression of other GPI-anchored proteins. 19 The defect induced by CAM-PATH-1H may be different in B and T cells. In B cells, the defect in CD52 expression appears to be reversible in vitro. CD52-negative T cells showed no such plasticity. 22, 23 Response to CAMPATH-1H treatment is not uniform. Quantitative estimates of CD52 expression on B and T cells is predictive of treatment response: the greater the expression, the greater the response. 5 There may be a variation in CD52 expression in the normal lymphocyte population, with a small proportion of cells being CD52-negative at any one time. By depleting the positive cells, the negatives expand.
Other MoAb therapies can exert selective pressure in favor of small populations of clonal tumor cells that lack specific surface antigens resulting in tumor escape and relapse. The emergence of CD20-negative clones has been reported in B cell lymphomas treated with rituximab. 24 DNA analysis confirmed that the transformed lymphoma originated from the primary malignant clone. CD20 negativity was not simply due to competitive inhibition of the CD20 binding sites by bound rituximab.
One explanation for the detection of only CD52-negative cells from a patient following CAMPATH-1H treatment could be that bound antibody competes with the detecting antibody used for flow cytometry. In our first patient, CD52 negativity cannot be due to competitive inhibition of the CD52 binding sites by bound residual CAMPATH-1H, because the clonal cells remained CD52-negative more than 7 weeks after the discontinuation of CAMPATH-1H. The half-life of CAMPATH-1H at 4 weeks of treatment has been determined to range from 34 to 60 h: at 7.5 mg/week, t . = 34 ± 17 h; at 24 mg/week, t . = 57 ± 25 h; at 75 mg/week, t . = 60 ± 36 h; at 240 mg/week, t . = 53 ± 38 h. The overall mean is 53 ± 31 h. At 1 week of treatment, the mean half-life is 42 ± 27 h (D Rodriguez, Millennium Pharmaceutical, personal communication, August, 2000) . It is expected that after 5 half-lives (480 h or 20 days), no drug would be available to bind the neoplastic lymphocytes or competitively block antigenic sites and yield false CD52-negative status in flow cytometry. Additionally, at this stage no CAMPATH-1H-bound cells should remain in the circulation. While the half-life of CD4 + and CD8 + T-lymphocytes has been found to be 87 and 77 days, respectively, 25 cells with bound CAMPATH-1H are cleared from the body almost immediately after treatment. This is the first reported case in which CD52-negative leukemic T cells emerged following CAMPATH-1H treatment. Failure of a similar nature has been reported using CAMPATH-1G and CAMPATH-1M in an in vivo/ex vivo attempt to purge Leukemia an allograft of T cells. A CD52-negative T cell population emerged that resulted in graft rejection. 26 This case report suggests that the emergence of CD52-negative malignant clones can occur following CAMPATH-1H therapy. While not a part of the current study, determination of the expression of GPI-linked antigens CD55 and CD59 (or lack thereof) would most definitively make the case that GPIdeficient cells had emerged. Therefore, if patients progress on therapy, flow cytometric evaluation for CD52, CD55 and CD59 should be considered and further treatment decisions made based upon the results.
